POPULARITY
3 episodes with Indolent
7 episodes with Indolent
3 episodes with Indolent
2 episodes with Indolent
2 episodes with Indolent
7 episodes with Indolent
5 episodes with Indolent
2 episodes with Indolent
2 episodes with Indolent
Indolent systemic mastocytosis (ISM) is a rare form of systemic mastocytosis (SM) caused by an abnormal buildup of mast cells throughout the body. What causes ISM, and how is it diagnosed? In this episode, we speak with Aaron Gerds, MD, Associate Professor of Medicine in Hematology and Medical Oncology at the Cleveland Clinic Cancer Institute, about the signs and symptoms of ISM, the diagnostic process, and how ISM differs from other forms of systemic mastocytosis. We also hear from Candice Pauley, an ISM patient and co-host of the Mast Cast Pod, who shares her journey to diagnosis, her experience living with the disease, and the challenges of navigating a rare condition. Credits Host: Neha Pathak, MD, FACP, DipABLM Producer/Editor: Matt Stillo Show Notes: Lauren Summers Guests: Aaron Gerds, MD; Candice Pauley See omnystudio.com/listener for privacy information.
It's the one where David interviews Scott Lynch of Indolent Records.They discuss Scott's introduction to punk rock, and his journey to running his own label.They also get into discussing the attention to detail put into each vinyl release on Indolent Records.Be sure to join our FREE Patreon and tune in for Scott's special appearance on Growing Up Punk: Radio, Radio.Sorry for the audio issues, we had plenty of technical issues getting this interview to happen.JOIN OUR FREE PATREONINSTAGRAMINDOLENT ON IGINDOLENT ON BANDCAMP
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients' quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM.
Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients' quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM.
Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients' quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM.
In the latest installment of Dermatology Times' video series, the Derm Dispatch, host Renata Block, DMSc, MMS, PA-C, sits down with indolent systemic mastocytosis patient advocate Suki Tipp to examine the clinical, emotional, and financial toll of delayed diagnosis—and the critical role dermatology clinicians can play in recognizing this rare disease earlier.Now a vocal advocate, Tipp encourages dermatology clinicians to consider systemic mastocytosis in patients presenting with recurrent urticaria, flushing, unexplained brown macules, and systemic symptoms.
Are you missing indolent systemic mastocytosis (ISM)? Learn key clues and best practices in our expert-led program. Credit available for this activity expires: 1/05/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/patient-centered-approaches-indolent-systemic-mastocytosis-2025a100106v?ecd=bdc_podcast_libsyn_mscpedu
Indolent Systemic Mastocytosis (ISM) is a rare but often underrecognized clonal mast cell disorder. From random hives to gut pain and brain fog, ISM can feel like a medical mystery. We continue our review of “Management of indolent mastocytosis and mast cell activation syndrome - A clinical yardstick,” published in June 2025 in The Annals of Allergy, Asthma & Immunology. This is Part 2 of our discussion, with a focus on indolent systemic mastocytosis. We look at what causes it, how it's diagnosed, and how to manage symptoms and improve quality of life. In this episode, we break down this complex mast cell disease and how doctors use baseline serum tryptase, KIT D816V testing, and HaT screening to find answers. Plus, we explain how treatments like antihistamines, mast cell stabilizers, and avapritinib can help people live better with ISM.
Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis
Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis
Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis
Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis
Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis
Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis
Show #2461 Show Notes: Ekklesia Bible Study Part 3 (Thursday): https://thelibertyactionnetwork.com/event/ekklesia-bible-study-3/ Support Hadassah: Harry & Hadassah Wilkinson 528 E. Bradshaw St. Dixon, IL 61021 Ivermectin covered up, but no arrests: […]
What happens when you target the root cause of indolent systemic mastocytosis? In this episode of The Itch Review, we unpack key findings from the article “Avapritinib versus Placebo in Indolent Systemic Mastocytosis,” published on May 23, 2023, in NEJM Evidence. Indolent Systemic Mastocytosis (ISM) is a rare chronic disease with life-altering symptoms. Until recently, treatment options were limited. We break down new data from Part 2 of the PIONEER study, which evaluated Avapritinib, a targeted therapy designed to inhibit the KIT D816V mutation that drives ISM. Dr. Gupta and Dr. Blaiss explain how Avapritinib works, how the study was designed, and what outcomes were measured, including the Total Symptom Score (TSS). Most importantly, we explore what this treatment could mean for patients with moderate to severe ISM. INFOGRAPHIC What we cover in our episode about avapritinib versus placebo: Understanding ISM: How the KIT D816V mutation causes overproduction and overactivation of mast cells. Why current treatment falls short: The limitations of best supportive care and why many patients remain symptomatic despite multiple medications. How Avapritinib works: A tyrosine kinase inhibitor that targets the KIT mutation directly, aiming to reduce mast cell activation at its source. Inside the PIONEER trial: Study design, eligibility criteria, and how outcomes like Total Symptom Score (TSS) and serum tryptase were measured. What the data showed: Improvements in symptoms, lab markers, and quality of life and what this could mean for long-term ISM care. The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. Made in partnership with The Allergy & Asthma Network. Thanks to Blueprint Medicines for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.
Do patients and their healthcare teams view the impact of indolent systemic mastocytosis on quality of life in the same way? In this episode of The Itch Review, we unpack key findings from a May 4, 2025, descriptive study from The Journal of the Advanced Practitioner in Oncology, “Patient and Advanced Practitioner Perspectives on Symptom Burden and Symptom Management in Indolent Systemic Mastocytosis.” Is there a disconnect between what patients feel and what providers think when it comes to indolent systemic mastocytosis (ISM)? A new study suggests yes, revealing a mismatch between how patients and advanced practitioners (APs) perceive disease control and what that means for care. This episode dives into whether research like this could help bridge the gap between patient experience and clinical perspective. What we cover in our episode about the indolent systemic mastocytosis: Understanding ISM: What makes indolent systemic mastocytosis a unique multisystem condition? Symptom burden explained: Frequency, severity, duration, distress, and functional interference. Patient vs practitioner views: Understanding the most impactful symptoms differs from patient to AP. Practical tools: The Indolent Systemic Mastocytosis-Symptom Assessment Form (ISM-SAF) is a validated instrument that can be used to determine symptoms and severity. Barriers and solutions: Why tracking symptoms is hard and how clinics can improve coordination. AP-focused Toolkit: Resources to help nurse practitioners, PAs, and pharmacists provide patient-centered ISM care. GET THE INFOGRAPHIC HERE *** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores the latest allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. *** This podcast is made in partnership with The Allergy & Asthma Network. Thanks to Blueprint Medicines for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.
This podcast explores Mast Cell Disease, and we're learning more about this disease directly from someone living with it. Our guest, Rachael Rose, is a patient living with Indolent Systemic Mastocytosis. She will share her journey from diagnosis to daily living with this condition. Resources to keep you in the know:Systemic Mastocytosis - All Variants (TMS for A Cure)You can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: Blueprint MedicinesThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!
Show Notes This month, the Skin Flint team welcome RCVS & European Specialist Debbie Gow to the platform to explore Eosinophilic granuloma complex (EGC). (00:00) John Sue and Paul introduce the podcast. Chapter 1 – What on Earth Is Eosinophilic Granuloma Complex? (02:55) Sue welcomes Debbie Gow to the podcast and invites her to introduce herself. Debbie shares that she is a specialist in veterinary dermatology, working at a busy referral hospital outside Edinburgh. She describes her role in setting up the dermatology service, working with a resident and derm nurse, and her continued involvement in CPD and writing. (04:05) Sue introduces the topic: eosinophilic granuloma complex (EGC) in cats. She jokes that it's sometimes referred to as “eosinophilic granuloma confusion” due to its complexity and terminology. She asks Debbie to break it down explaining that EGC is an umbrella term for three lesion types: Linear granulomas: Seen on the backs of legs, chin, or in the mouth. May or may not be itchy. Plaques: Often pruritic, ulcerated, and secondarily infected. Found on the ventrum or medial thighs. Indolent ulcers: Located on the upper lip, may appear crater-like. (07:28) Sue asks about miliary dermatitis. Debbie considers it a separate reaction pattern, not part of EGC, though also common and allergy-associated. (08:15) John asks about age, breed, or sex predispositions. Debbie explains that while any cat can be affected, young adult cats (6 months to 5 years) are most likely to develop these lesions. Females may be slightly overrepresented, but evidence is limited. (09:27) John inquires about geographical prevalence. Debbie confirms EGC is seen globally wherever cats are present and exposed to allergy triggers. Chapter 2 – Lookalikes, Lip Lesions & Licking Cats: Sorting the EGC Puzzle (10:21) Sue asks whether EGC lesions are pathognomonic or if there are important differentials. Debbie stresses the importance of not assuming a diagnosis without investigation whilst they can have a classical appearance: Cytology is key to identifying eosinophils. Differentials include squamous cell carcinoma (particularly for lip ulcers), mycobacteria, fungal infections, and viral diseases. (12:37) Sue asks about a minimum diagnostic approach. Debbie advises: Cytology Wood's lamp and trichogram to rule out dermatophytosis Consideration of biopsies if in doubt (14:08) Sue asks how to perform cytology. Debbie describes: Tape prep for dry lesions Cotton bud for moist/crusted areas Direct impression with a slide (14:59) Sue asks how often infection is present. Debbie says: Infections are uncommon but more likely with plaques due to licking Cytology helps assess if antibiotics are needed Most cases are treated with anti-inflammatories rather than antibiotics (16:52) John asks about allergic patterns in cats. Debbie describes four main reaction patterns: Miliary dermatitis Head and neck pruritus Ventral overgrooming Eosinophilic lesions She notes cats may display multiple patterns and also non-skin signs like conjunctivitis, otitis, or sneezing. (19:02) John asks if specific allergies present with specific signs. Debbie says it's inconsistent. While flea allergy is often associated with miliary dermatitis and food allergy with head/neck pruritus, patterns vary and aren't reliable for diagnosis. Chapter 3 – Practical Approaches: From Kitchen Floor to Referral Door (21:23) John asks what owners might notice or try at home. Debbie recommends: Observing behaviour Keeping a diary Ensuring flea control Considering recent diet or environmental changes (23:30) Sue asks about food trial myths. Debbie emphasises: Over-the-counter “hypoallergenic” foods are not suitable for true food trials Prescription hydrolysed diets or novel proteins (e.g. ostrich, kangaroo, crocodile) are required Food trials should run for ~8 weeks She also recommends: Treat toppers to help encourage eating Short-term feeding is usually nutritionally safe Veterinary nutritionist input for longer-term plans (28:43) Sue asks how to start a food trial if a cat is self-traumatising. Debbie uses concurrent systemic treatment (usually steroids) to control inflammation during the trial, tapering meds over 4–6 weeks if possible. (30:05) John asks for the first steps as a guide for primary care vets. Debbie recommends her first steps would be to rule out ectoparasites with full household flea control, possibly whilst beginning topical/systemic treatment as needed for comfort (32:10) Sue asks what to do when left with suspected environmental allergy. Debbie describes: Referral approach: Intradermal testing and immunotherapy if cost allows (40–75% success rate) Primary care approach: Use steroids at the lowest effective dose Importance of prioritising flea control and food trial first as they are often curative (36:50) Sue and Debbie have a healthy debate on the relative benefits of allergy testing when immunotherapy is not being considered as an option. (41:08) John wraps up the episode, thanking Debbie for simplifying a complex topic and helping listeners better understand eosinophilic granuloma complex in cats. John asks Paul and Sue another probing - if not questionable - question.
CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/differential-diagnosis-of-indolent-systemic-mastocytosis/32713/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/differential-diagnosis-of-indolent-systemic-mastocytosis/32713/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.
Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey
Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey
Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey
Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey
Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey
Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey
In this episode, host Alyssa Watson, DVM, welcomes back DJ Haeussler, DVM, MS, DACVO, to talk about his recent Clinician's Brief article, “Diamond Burr Debridement for Indolent Corneal Ulcers.” Dr. Haeussler starts by reviewing all the practical details about indolent ulcers, including how to diagnose them and initiate treatment. Then, for the cases that don't respond, he explains when and how to perform diamond burr debridement using a dental handpiece.Resource:https://www.cliniciansbrief.com/article/corneal-ulcers-erosion-treatment-corneaContact:podcast@vetmedux.comWhere To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist
CME credits: 0.25 Valid until: 24-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-approach-to-diagnosing-and-managing-indolent-systemic-mastocytosis-the-changing-landscape/18090/ Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of care for ISM and discuss why allergists, hematologists, and gastroenterologists are at the vanguard of this change.=
CME credits: 0.50 Valid until: 24-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-indolent-systemic-mastocytosis-a-multidisciplinary-case-review/18089/ New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.=
Fr. Mina continues by discussing the virtues of marriage in chapter 5 of the book of Proverbs, which states: "There is newness in marriage." Lust is there all around us and at the tips of our fingers. However, the holy mystery of marriage offers an opportunity to encounter a new kind of love—an unfathomably selfless love. This is the "running water" that King Solomon encourages us to drink from, as stated in Proverbs 5:15. The proverb concludes by emphasizing the value of privacy and stressing how much God values family life because it is the first system He established and was raised in. Fr. Mina divides the first three sorts of men in Proverbs 6 as follows: 1) The financially strapped 2) Indolent 3) A source of trouble. Fr. Mina discusses the significance of giving without expecting anything in return as he wraps up his discussion on the first category of men.
In this week's episode we'll discuss extended follow-up from the ZUMA-5 trial of axicabtagene ciloleucel, or axi-cel. Then we'll learn about the role of platelets in binding and clearing senescent red blood cells. Finally, we'll hear about a new risk stratification strategy for lymphomas of the central nervous system, or CNS.
Full article: https://ajronline.org/doi/10.2214/AJR.23.30496 Xiao Xiao Tong discusses a study that conducted a comparative analysis between patients who underwent multiparametric MRI and those who underwent biparametric MRI, in terms of NPV. No statistically significant difference was observed between these two groups, including in subgroups of patients on active surveillance and patients with no prior prostate cancer history.
This episode Tim is joined by one of the iconic figures from the 1990s British indie rock scene. Fronting the band Sleeper, Louise Wener was one of the biggest female stars in the Britpop era. She takes Tim through the band's second album, the It Girl, which was released in 1996 and reached the top 5 of the album charts, going platinum in the UK. It is one of the lasting records of the era and they discuss standing out in a music world that was considerably dominated by male bands, journalists and execs, escaping life the suburbs for the stage and their love of Blondie.The It Girl was released on 6th May 1996 on Indolent.
Frank Siebenhaar, MD - Indolent Isn't Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
Frank Siebenhaar, MD - Indolent Isn't Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
Frank Siebenhaar, MD - Indolent Isn't Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.
Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL; and Outline clinical considerations for the use of CD19-directed CAR T cell therapies for relapsed/refractory indolent FL and CLL/SLL.
Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Richard Newcomb, MD!
Today's crossword is based on a suffusion of sneaky prefixes that underline the beauty, and the beautiful inconsistency, of the English language. Also, it's Tuesday, meaning it's time for yet another Triplet Tuesday segment in which Mike demonstrates his lack of, to put it succinctly, knowledge. Deets inside, so download, listen up ,and enjoy!Contact Info:We love listener mail! Drop us a line, crosswordpodcast@icloud.com.Also, we're on FaceBook, so feel free to drop by there and strike up a conversation!
Our guest this week has lived with a slow growing, incurable cancer for the past two decades. She tells us about how she has modified her lifestyle using nutrition as well as a combination of distraction and mindfulness to grapple with the mental challenges of uncertainty. She talks about the idea of “median survival statistics” and how a powerful essay by Stephen J. Gould helped her see those stats in a different light. She also discusses the evolution of treatment and imaging over her 22 years as a patient, and the powerful scientific progress that has been made during that time. Key highlights: The unique nature of indolent (slow growing) cancer and living as a patient for +20 years Examining median survival stats and Stephen Gould's paper “The Median Isn't the Message” Nutrition modifications and the shift to a plant-based diet Grappling with uncertainty using Distraction + Mindfulness The evolution of treatment and imaging in her cancer over the past 21 years About our guest: Rowan Carlson is an aquatic ecologist who was diagnosed in 2001 with an incurable form of Non-Hodgkin's lymphoma that requires repeated treatment. Thanks to her doctors who carefully timed her treatments and family and friends who supported her in a myriad of different ways, she continued teaching at the college level and conducting research abroad through 2019. Now retired from teaching, she gardens episodically, hikes daily, demonstrates monthly for climate action, and habitually writes scientific papers. Key Moments: 7 minutes 50 seconds: I heard a nutritionist speaking to a group of cancer patients at a local wellness center. And I found that what she was recommending was so different from the way I ate that I thought it was radical. So I made appointments with two other nutritionists specializing in cancer patients, and all three of them were advocating the same healthful diet. They were advocating a plant-based diet avoiding red meat and processed meat and filling your plate with vegetables. 15 minutes 35 seconds: There's a very powerful essay written by a famous biologist, Stephen J. Gould, and the title of that essay is “The Median Isn't the Message.” He was prompted to write this essay because he had just been diagnosed with a very rare form of GI cancer, and he quickly dug up a medical paper and learned that the median survivorship of this cancer was 8 months. The essay describes how he dealt with this. He convinced himself that he would live longer than that, and most people do live longer than the median. He lived for another 20 years and died from a different type of cancer. 17 minutes 24 seconds: What has really helped me since that first year after my diagnosis are two things. One is distraction. I distract myself by keeping very busy on projects that are larger than myself, for instance writing scientific papers and more recently working with three climate action groups. I find this work very fulfilling, and it does distract me, but you can keep yourself too busy and that can rob you of time with family and friends, which is also important, so I try to balance distraction with something called mindfulness. Mindfulness is the idea of living in the moment, and it's been very helpful for me. Visit the Manta Cares website Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions. --- Support this podcast: https://podcasters.spotify.com/pod/show/manta-cares/support
Editor-in-Chief, Robert Amdur, MD, discusses primary radiotherapy for early-stage Non-Hodgkin's Lymphoma of Early Stage and Indolent Histology. The discussion begins with an explanation of lymphoma classification and then reviews two papers published in PRO: “Prognostic Effect of Systemic Therapy and Radiation Therapy in Stage I Nodal Marginal Zone Lymphoma” (2023, Issue 1, January/February) and “Underutilization of Radiation Therapy in Early-stage Marginal Zone Lymphoma Negatively Impacts Overall Survival” (2016, Issue 4, July/August).
CME credits: 0.25 Valid until: 07-10-2023 Claim your CME credit at https://reachmd.com/programs/cme/indolent-systemic-mastocytosis-ism-treatment-options-for-ism/13995/ Indolent systemic mastocytosis is a rare disease often overlooked in the general healthcare setting. Drs. Deepti Radia and Cem Akin outline diagnostic criteria, signs and symptoms, and diagnostic tests to confirm diagnosis.
CME credits: 0.25 Valid until: 15-09-2023 Claim your CME credit at https://reachmd.com/programs/cme/indolent-systemic-mastocytosis-ism-tools-to-diagnose-ism/13994/ It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
CME credits: 0.25 Valid until: 15-09-2023 Claim your CME credit at https://reachmd.com/programs/cme/indolent-systemic-mastocytosis-ism-updates-in-identification-diagnosis-and-treatment/13994/ It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Retina specialists may wish to turn to the literature to learn more about multifocal, indolent, nonprogressive choroidal lesions. Let the New Retina Radio Journal Club with VBS help you out. Moderator Kyle Kovacs, MD, is joined by Cynthia Qian, MD, and David Xu, MD, to review two recent papers on this atypical presentation.
The 521st of a series of weekly radio programmes created by :zoviet*france: First broadcast 28 June 2022 by Resonance 104.4 FM, and CJMP 90.1 FM Thanks to the artists included here for their fine work. track list 00 Bad Poet - Intro 01 Mike Lazarev - If I Could Be your Tears 02 Peregrino - El silencio de los animales 03 Pauline Oliveros & Reynols - Astral Netcast Pigeon 04 Leticia Castaneda - Complacent, Indolent or Asleep 05 Vladimir Ussachevsky - Computer Piece No. 1 06 Andrew Sharpley - Microscope 07 Nula.cc - Abante Limbo 08 Keith de Mendonca - Ice Heel 09 Saito Koji - Anne ++ Bad Poet - Outro
TWiV reviews the emergence of remdesivir-resistant SARS-CoV-2 during treatment of a persistently infected immunocompromised patient, and how altered TMPRSS2 utilization by the Omicron variant influences infectivity and fusion. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode ASV 2022 Emergence of remdesivir resistance (Nature Comm) How to stall a copy machine (TWiV 819) Omicron altered TMPRSS2 usage (Nature) Timestamps by Jolene. Thanks! Weekly Picks Brianne – NSURP 2022 Kathy – Virology Jobs Rich – 10 Steps from Seed to Cup (Graphic) Alan – Fathoms: The World in The Whale, by Rebecca Giggs Vincent – Worldwaterday.org Listener Picks Jeremy – Archaeology of Light Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv
TWiV reviews the emergence of remdesivir-resistant SARS-CoV-2 during treatment of a persistently infected immunocompromised patient, and how altered TMPRSS2 utilization by the Omicron variant influences infectivity and fusion. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode ASV 2022 Emergence of remdesivir resistance (Nature Comm) How to stall a copy machine (TWiV 819) Omicron altered TMPRSS2 usage (Nature) Timestamps by Jolene. Thanks! Weekly Picks Brianne – NSURP 2022 Kathy – Virology Jobs Rich – 10 Steps from Seed to Cup (Graphic) Alan – Fathoms: The World in The Whale, by Rebecca Giggs Vincent – Worldwaterday.org Listener Picks Jeremy – Archaeology of Light Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv
© 2020-2026 Ivy Podcast Discovery LLC
